By StartupChi Team | March 6, 2024

Introduction

Xeris Biopharma, a pioneering player in the biotechnology sector, has successfully completed a post-IPO debt funding round, raising a significant $200 million to bolster its innovative therapies aimed at endocrinology, neurology, and gastroenterology. This round not only underscores the growing investor confidence in the company but also signals a critical leap towards expanding its market presence in the competitive health care landscape.

Background

Founded to tackle persistent challenges in the pharmaceutical industry, Xeris Biopharma has made a name for itself by developing groundbreaking therapies that address unmet medical needs. With a focus on areas such as diabetes management, the company has navigated the complexity of drug delivery systems since its inception. The founders’ vision was to create a more effective treatment pipeline, and over the years, Xeris has successfully evolved into an industry leader, forging a path in a market where conventional approaches have often fallen short.

Funding Details

The recent funding round, which brings Xeris Biopharma’s total funding to $548.5 million, was entirely backed by Hayfin Capital Management. Following a strong IPO, this post-IPO debt signifies not only financial stability but also opens avenues for further investments in therapeutic development. Although the exact pre-money valuation for this round has not been disclosed, the infusion of capital is poised to reinforce Xeris Biopharma’s capabilities and product offerings.

Competitive Landscape

In a crowded market faced with contenders from both established and emerging biopharmaceutical companies, Xeris Biopharma distinguishes itself through its innovative drug formulations and delivery mechanisms. As it battles for market share with rivals in the diabetes sector and beyond, Xeris’s strong revenue range of $100M to $500M positions it favorably, allowing it to leverage this funding to escalate its competitive edge further.

Future Plans

The newly acquired funding will be instrumental in driving product development, expanding operational capabilities, and enhancing marketing strategies. Xeris Biopharma aims to fortify its portfolio with even more robust therapies tailored for complex conditions, while also seeking to broaden its geographic footprint—ultimately working towards improved health outcomes for patients globally.

To learn more about Xeris Biopharma and its innovative approach to biopharmaceuticals, visit their website at xerispharma.com.

Post-IPO Debt – Xeris Biopharma:

• Organization Name: Xeris Biopharma
• Organization Description: Xeris Biopharma is a pharmaceutical company that develops therapies for patients in endocrinology, neurology, and gastroenterology.
• Website: xerispharma.com
• Funding Type: Post-IPO Debt
• Funding Round: Post-IPO Debt – Xeris Biopharma
• Money Raised: $200,000,000
• Announced Date: Mar 6, 2024
• Funding Stage: —
• Pre-Money Valuation: —
• Equity-Only Funding: No
• Industries: Biotechnology, Diabetes, Health Care, Pharmaceutical
• Revenue: $100M to $500M
• Total Funding: $548,500,000
• Funding Status: IPO
• Number of Funding Rounds: 14
• Lead Investor:
• Investors: , Hayfin Capital Management, ,
• Number of Investors: 1
• Number of Partner Investors: —